Welcome to our dedicated page for GUARDION HLTH SCIENCS news (Ticker: GHSI), a resource for investors and traders seeking the latest updates and insights on GUARDION HLTH SCIENCS stock.
Guardion Health Sciences, Inc. (Nasdaq: GHSI) is a pioneering clinical nutrition company dedicated to improving health through science-based, clinically supported dietary supplements and medical foods. Specializing in solutions for age-related health issues, the company leverages the latest advancements in science and technology to address conditions like age-related macular degeneration (AMD), bone health, eye health, cardiovascular health, and brain health.
Guardion's flagship product, Lumega-Z, is a scientifically formulated medical food designed to restore and maintain macular protective pigment, crucial for combating AMD. Ingredients in Lumega-Z are also believed to support other eye conditions, adding to the product's broad utility.
Core Offerings
- Clinically supported dietary supplements
- Medical foods
The company's product portfolio includes essential nutrients like Calcium, Vitamin D, Vitamin K, Carotenoids, and Omega-3s. These are designed to deliver comprehensive health benefits to consumers, healthcare professionals, and their patients.
Recent Achievements
- The Viactiv® product line reported a 6% revenue increase for the six months ended June 30, 2023, compared to the same period in 2022.
- Robust growth in the Amazon sales channel, a testament to the company's focus on eCommerce initiatives.
In 2024, the company is undergoing significant developments. Institutional Shareholder Services (ISS) has recommended that stockholders vote in favor of proposals related to the sale of the company’s Viactiv brand and subsequent liquidation and dissolution. These proposals promise potential liquidating cash distributions that are expected to surpass recent stock prices, signaling a strategic pivot and potential value generation for stockholders.
Guardion Health Sciences actively collaborates with healthcare professionals and utilizes the expertise of its Science Advisory Board to educate the public on the importance of medical foods and nutrition. This commitment to health education underscores the company's mission to promote overall well-being through scientifically validated nutritional solutions.
Contact Information
For more details, you can reach out to Investor Relations at investors@guardionhealth.com or call 1-800-873-5141 Ext 208.
Guardion Health Sciences (GHSI) announced a 1-for-6 reverse stock split effective March 1, 2021, to comply with Nasdaq's minimum bid price rule. The company also completed at-the-market financings, raising a total of $37.2 million, providing it with over $44 million in cash for future growth and acquisitions. The reverse split aims to enhance the attractiveness of GHSI's stock and maintain compliance for continued listing on Nasdaq. The company has approximately 24.4 million shares outstanding post-split, with a focus on ocular health and clinical nutrition.
Guardion Health Sciences (GHSI) announced that its exclusive distributor in Malaysia, Ho Wah Genting Berhad (HWGB), received product registration approval for the immune support dietary supplement Astramern Astra H from the Malaysian National Pharmaceutical Regulatory Agency. This approval, valid for five years, signifies an important step toward commercialization and allows HWGB to package it with another product, Nutra V, enhancing their immune support offerings. Guardion aims to expand its presence in the Asian nutraceutical market through strategic partnerships and product development.
Guardion Health Sciences (GHSI) announced it received a Nasdaq extension until March 15, 2021, to comply with the $1.00 Minimum Bid Price Rule. The company expressed optimism regarding a recent share price increase, believing it may regain compliance soon. Should the share price fail to meet the requirements, a reverse stock split, previously approved by shareholders, will be enacted to maintain Nasdaq listing. The company focuses on ocular health through clinically supported nutrition and medical devices. Compliance with Nasdaq rules remains crucial for GHSI's market presence.
Guardion Health Sciences (Nasdaq: GHSI) announces the appointment of Bret Scholtes as President and CEO, effective January 6, 2021. Scholtes, with nearly a decade in the nutritional products industry, is expected to drive growth and profitability. His previous role at Omega Protein Corporation saw significant revenue and stock price increases. The Board aims to align Scholtes's compensation with shareholder value objectives. The leadership change comes at a challenging time but promises a focus on product development and market expansion.
Guardion Health Sciences (GHSI) is advancing its new vision support drink, Epiq-V, targeting both adult and youth markets. The drink, which contains Lutein, aims to support ocular health and enhance attention for video gaming. Following successful initial testing, final testing is expected to conclude by Q1 2021, with product availability projected 12 to 16 weeks post-testing. Trademark registration for Epiq-V has been secured in China, with U.S. registration pending. The company’s strategy emphasizes innovative product development for domestic and international markets.
Guardion Health Sciences, Inc. (GHSI) reported a significant revenue increase of 57% for the three months ending September 30, 2020, totaling approximately $253,000, up from $161,000 year-over-year. Medical device sales surged by 147% while medical foods grew by 26%. Despite these gains, the net loss decreased to approximately ($2,143,000) or ($0.02) per share. The company is poised for potential Nasdaq delisting due to a share price below $1.00 and is appealing for an extension. Notably, promising clinical data for Lumega-Z® supports product differentiation in the ocular health market.
Guardion Health Sciences announced a new study published on October 26, 2020, in the journal Nutrients. The research compared the efficacy of Lumega-Z®, Guardion's micronized carotenoid liquid supplement, against the AREDS-2 soft gel (PreserVision®). Conducted over six months, results showed Lumega-Z® significantly improved contrast sensitivity (p < 0.001), while AREDS-2 showed no significant change (p > 0.05). The study indicates Lumega-Z® may better meet the needs of those at risk for age-related macular degeneration. Dr. David Evans highlighted the rapid benefits of Lumega-Z® in visual performance.
Guardion Health Sciences, Inc. (NASDAQ: GHSI) is urging stockholders to vote for Proposal 4 at the Annual Stockholders’ Meeting on October 29, 2020. This proposal seeks an extension to effectuate a reverse stock split to maintain compliance with Nasdaq's minimum bid price requirement of $1.00 per share, crucial to avoid potential delisting by November 30, 2020. If declined, delisting risks would increase, adversely impacting stock liquidity. The board stresses that every vote is vital for the company's future.
Guardion Health Sciences (GHSI) has announced an investigator-initiated clinical trial for Lumega-Z, its flagship nutritional product, aimed at evaluating its impact on restoring macular pigment and stabilizing vision. Conducted by Dr. Rick Sponsel, the trial will involve glaucoma patients comparing those taking Lumega-Z daily against a control group over 12 months. Dr. Sponsel's expertise in ocular physiology enhances the study's credibility. Guardion aims to differentiate its offerings through measurable clinical outcomes to influence the ocular health market.
Guardion Health Sciences, Inc. (NASDAQ: GHSI) has announced strategic initiatives to enhance shareholder value. The company will focus on differentiation of brands and the integration of an E-commerce platform, alongside expanding clinically supported nutritional products internationally. Guardion has retained Corporate Finance Associates as a financial advisor to explore strategic transactions. The Board has also formed a Strategy Committee to assess business opportunities. Additionally, Guardion is committed to developing direct-to-consumer sales and evidence-based therapies while enhancing its management team.
FAQ
What is the current stock price of GUARDION HLTH SCIENCS (GHSI)?
What is the market cap of GUARDION HLTH SCIENCS (GHSI)?
What does Guardion Health Sciences, Inc. specialize in?
What is Lumega-Z?
What recent financial achievements has Guardion Health Sciences reported?
What nutrients are included in Guardion's products?
What are the latest developments for Guardion Health Sciences in 2024?
How is Guardion Health Sciences addressing age-related health issues?
Who can benefit from Guardion Health Sciences' products?
How can I contact Guardion Health Sciences for more information?
What role does the Science Advisory Board play at Guardion Health Sciences?
What focus areas does Guardion Health Sciences cover in their product offerings?
